- Home
- URGN vs AGS Comparison
URGN vs AGS Comparison
Compare URGN & AGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AGS
- Stock Information
- Founded
- URGN 2004
- AGS 2005
- Country
- URGN United States
- AGS United States
- Employees
- URGN N/A
- AGS N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AGS Miscellaneous manufacturing industries
- Sector
- URGN Health Care
- AGS Consumer Discretionary
- Exchange
- URGN Nasdaq
- AGS Nasdaq
- Market Cap
- URGN 547.1M
- AGS 455.5M
- IPO Year
- URGN 2017
- AGS 2018
- Fundamental
- Price
- URGN $11.19
- AGS $11.63
- Analyst Decision
- URGN Strong Buy
- AGS Hold
- Analyst Count
- URGN 5
- AGS 4
- Target Price
- URGN $44.50
- AGS $12.63
- AVG Volume (30 Days)
- URGN 456.4K
- AGS 180.5K
- Earning Date
- URGN 11-06-2024
- AGS 11-07-2024
- Dividend Yield
- URGN N/A
- AGS N/A
- EPS Growth
- URGN N/A
- AGS 150.52
- EPS
- URGN N/A
- AGS 0.17
- Revenue
- URGN $89,363,000.00
- AGS $386,033,000.00
- Revenue This Year
- URGN $14.43
- AGS $10.08
- Revenue Next Year
- URGN $44.44
- AGS $4.97
- P/E Ratio
- URGN N/A
- AGS $68.45
- Revenue Growth
- URGN 15.64
- AGS 12.18
- 52 Week Low
- URGN $10.60
- AGS $7.11
- 52 Week High
- URGN $20.70
- AGS $11.75
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- AGS 55.90
- Support Level
- URGN $11.93
- AGS $11.60
- Resistance Level
- URGN $12.78
- AGS $11.71
- Average True Range (ATR)
- URGN 0.71
- AGS 0.04
- MACD
- URGN -0.05
- AGS -0.01
- Stochastic Oscillator
- URGN 1.36
- AGS 27.27
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AGS PlayAGS Inc.
PlayAGS Inc is a designer and supplier of gaming products and services for the gaming industry. The company mainly supplies electronic gaming machines (EGM), server-based systems and back-office systems which are used by casinos, and various gaming locations. Its operating segments are EGM, Table Products, and Interactive. The EGM segment offers a selection of video slot titles developed for the world-wide marketplace as well as EGM cabinets. Its Table Products segments include live proprietary table games and side bets, as well as ancillary table products. The Interactive segment consists of delivering games through mobile apps such as Lucky Play Casino and Vegas Fever. It earns a majority of its revenue from Electronic Gaming Machines segment and geographically from the United States.